Thelansis

 Chronic kidney disease (CKD) is characterized by kidney damage lasting over three months, indicated by abnormal albumin excretion or decreased kidney function as measured by glomerular filtration rate (GFR). Diabetes and high blood pressure are its primary causes. In children, CKD typically results from structural anomalies or inherited conditions like polycystic kidney disease. CKD is categorized into five stages based on GFR test results. As the stages progress, kidney function declines. Slowing down kidney damage is crucial at each stage. Screening for CKD involves two standard tests: GFR and urine albumin. Metformin is the preferred treatment for type 2 diabetes with CKD, usually starting with an eGFR above 45 mL/min/1.73 m2 and continuing safely until it drops to 30 mL/min/1.73 m2. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists can reduce CKD progression. SGLT-2 inhibitors may slow CKD progression and reduce heart fail...

 Chronic kidney disease (CKD) is defined as the presence of kidney damage, manifested by abnormal albumin excretion or decreased kidney function, quantified by measured or estimated glomerular filtration rate (GFR), that persists for more than three months. ·        The prevalence of Chronic kidney disease (CKD) is 69.6 percent among people ages 66 and older who have CKD, compared to 34.7 percent among those who do not have CKD. ·        Women (15.93%) are more likely to have stages 1 to 4 CKD than men (13.52%). Thelansis’s “Chronic kidney Disease (CKD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic kidney Disease (CKD) tre...